Accelerating Access to Lenacapavir: Everyone has a role to play
View this email in your browser ([link removed])
[link removed] December 19, 2024
** Accelerating Access to Lenacapavir: Everyone has a role to play
------------------------------------------------------------
Dear Advocate,
This year, the HIV prevention community witnessed a landmark moment with the results of the lenacapavir (LEN) for PrEP PURPOSE 1 and 2 trials, which showed nearly complete protection against HIV. Named as “breakthrough of the year” by Science Magazine ([link removed]) , LEN’s every-six-month injectable dosing has the potential to transform the HIV response, but only if it is rolled out with speed, scale and equity. Gilead Sciences, the developer of LEN, has repeatedly stated that they will begin submitting applications to national regulatory agencies to market LEN for PrEP before the end of the year. WHO is also beginning to develop guidelines for LEN for PrEP. And just this week, PEPFAR and the Global Fund announced ([link removed]) a coordinated effort to reach two million people with access to LEN. So, the clock is
ticking and achieving this vision – and significantly reduce global HIV infections requires coordination at every level.
We released a new framework, the Gears of LE ([link removed]) N for PrEP Rollout ([link removed]) , which provides more details about all the moving parts needed to accelerate equitable access – and the necessary lubrication to ensure the world does not squander this opportunity. Read a new op-ed ([link removed]) penned by Jirair Ratevosian ([link removed]) and Mitchell Warren ([link removed]) in Devex describing this process and read more below about this framework and tools and strategies to support the advocacy needed.
[link removed]
The Gears of Lenacapavir for PrEP Rollout ([link removed]) underscores that each stakeholder—whether governments, donors, civil society, or manufacturers—must function like the gears in a finely-tuned clock. Everyone has a role to play–each component is essential, and only by working together in synchronization can we keep to time and ensure a seamless and impactful rollout.
read the framework ([link removed]) [link removed]
RECENT LEN FOR PREP NEWS
• The world has a new HIV prevention drug. Let's use it, Devex ([link removed])
• Global Fund, PEPFAR Announce Coordinated Effort to Reach 2 Million People with Lenacapavir for PrEP to Significantly Reduce Global HIV Infections ([link removed])
• Global Fund, PEPFAR to reach 2 million people with the 6-monthly long-acting injectable Lenacapavir for HIV prevention ([link removed]) , Global Prevention Coalition
• 2024 Breakthrough of the Year ([link removed]) , Science Magazine
• Gilead Agrees to Allow Generic Version of Groundbreaking HIV Shot in Poor Countries ([link removed]) , New York Times
Resources
[link removed]
Advocates' Guide
** The Lens on LEN: The Basics on Injectable Lenacapavir as PrEP
------------------------------------------------------------
This advocates’ primer provides background on the product, the trials (including results of both PURPOSE 1 and 2), key questions, and next steps.
Read more ([link removed]) [link removed]
[link removed]
podcast
** Lenacapavir: The case for investing in delivering HIV prevention
------------------------------------------------------------
AVAC’s PxPulse podcast goes deep on LEN for PrEP. Recorded just days before Gilead’s announcement ([link removed]) that PURPOSE 2 also found very high efficacy, Dr. Flavia Kiweewa, a principal investigator of PURPOSE 1, lays out the research findings and what they mean. And Chilufya Kasanda Hampongo ([link removed]) of Zambia’s Treatment Advocacy and Literacy Campaign and Mitchell Warren ([link removed]) of AVAC talk about how to change a long history of squandered opportunities to get rollout right.
listen now ([link removed]) [link removed]
[link removed]
webinar recording
** Update on Lenacapavir for PrEP
------------------------------------------------------------
AVAC hosted a webinar focused on updates for the PURPOSE trials. Gilead provided an overview of the PURPOSE 1 and 2 trial results and insight into the status of PURPOSE 3, 4, and 5.
view the recording ([link removed]) [link removed]
infographic
[link removed]
** An Overview of Lenacapavir PrEP Trials
------------------------------------------------------------
This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 ([link removed]) and PURPOSE 2 ([link removed]) .
Download the Graphic ([link removed]) [link removed]
[link removed]
Reel
** Choice, Not Miracles
------------------------------------------------------------
AVAC Communications Director, Kenyon Farrow ([link removed]) breaks down the potential of LEN to make choice a reality.
view on instagram ([link removed]) [link removed]
ADDITIONAL INFOGRAPHICS
• Moving a product to the real world ([link removed])
• LEN generics—Can we go faster? ([link removed])
• PrEP price comparison ([link removed])
• PrEP initiations by country worldwide ([link removed])
Lenacapavir isn’t just another medication; it could be a catalyst for transformation. Together, we can seize this pivotal moment to revolutionize HIV prevention, paving the way for a future where innovative tools like lenacapavir reach everyone who needs them.
Best,
AVAC
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed]) [link removed]
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423
[email protected] (mailto:
[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])
